Ovarian

First-in-class BRCA-positive Ovarian Cancer Medicine Lynparza® (olaparib) Receives Positive pan-Canadian Oncology Drug Review (pCODR) Recommendation for Provincial Reimbursement

(Yahoo! Finance) Sept 21, 2017 - AstraZeneca Canada is pleased to announce that the pan-Canadian Oncology Drug Review (pCODR) has provided an overwhelmingly positive clinical recommendation for the reimbursement of Lynparza® (olaparib), a first-of-its-kind treatment for BRCA-mutated ovarian cancer.

read article

Johnson & Johnson Talcum Powder Lawsuits Mount, As Ovarian Cancer Claims Exceed 870 in Federal Multidistrict Litigation, Reports Bernstein Liebhard LLP

(Business Insider) Sept 20, 2017 - Johnson & Johnson continues to face a growing number of product liability claims over the alleged association between its talcum powder products and ovarian cancer. According to an update provided by the U.S. Judicial Panel on Multidistrict Litigation (JPML) on September 15th, there are at least 878 talcum powder lawsuits pending in the U.S. District Court, District of New Jersey, where all federally-filed ovarian cancer claims involving Johnson & Johnson's products have been centralized for coordinated pretrial proceedings.

read article

Markey Physicians First to Perform Unique Procedure for Ovarian Cancer

(University of Kentucky) Sept 19, 2017 - Physicians at the University of Kentucky Markey Cancer Center are the first to perform a unique procedure to treat a rare and persistent type of ovarian cancer.

read article

Tesaro's Ovarian Cancer Drug Gets EU Agency Backing

(Reuters) Sept 15, 2017 - A European Medicines Agency (EMA) panel recommended the approval of Tesaro Inc’s key drug, niraparib, for the treatment of recurrent ovarian cancer.

read article

The Crisis in Gynecological Cancer Research

(New York Times/Living with Cancer) Sept 14, 2017 - We’re in an unusually productive phase for gynecological cancer research, but there has been a steep decline in clinical trials in the field.

read article

Clovis Oncology’s Rucaparib Ariel3 Study Data Published In The Lancet

(Clovis) Sept 13, 2017 - ARIEL3 study of rucaparib successfully achieved primary, key secondary and exploratory endpoints; company plans to submit a supplemental New Drug Application (sNDA) in the U.S. for maintenance treatment indication in ovarian cancer by the end of October 2017.

read corporate press release

A Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It

(Forbes) Sept 11, 2017 - Rubraca keeps many ovarian cancers in check. Could it work as maintenance treatment in pancreatic cancer?

read article

Rucaparib Boosts Progression-free Survival in BRCA Mutant Recurrent Ovarian Cancer

(ESMO 2017 Congress) Sept 8, 2017 - Rucaparib maintenance therapy increases progression-free survival in BRCA mutant recurrent ovarian cancer by 77%, according to late-breaking results from the ARIEL3 trial reported today at the ESMO 2017 Congress in Madrid.

read press release

Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017

(Clovis) Sept 7, 2017 - Clovis Oncology, Inc. announced the first presentation of a comprehensive dataset from its Phase 3 ARIEL3 study of rucaparib at the 2017 European Society for Medical Oncology (ESMO) Congress taking place in Madrid.

read corporate press release

Morphotek, Inc. Announces an Agreement with Fujirebio Diagnostics, Inc. to Commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab

(Yahoo! Finance) Sept 5, 2017 - Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into a collaboration and license agreement with Fujirebio Diagnostics, Inc. (Fujirebio Diagnostics) to validate and commercialize the CA125 II assay for use on the Lumipulse® Instrument System as a companion diagnostic to aid in the selection of ovarian cancer patients who may best respond to Morphotek's investigational antibody, farletuzumab.

read article

ICON8 Trial Reaffirms Standard Dosing in Ovarian Cancer Chemo

(ESMO 2017 Congress) Sept 4, 2017 - European women with ovarian cancer can safely stick to the standard three-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial to be presented at the ESMO 2017 Congress in Madrid.

read press release

ICER Assesses Cost-Effectiveness Of PARP Inhibitors

(BioCentury) Aug 31, 2017 - In an evidence report released Wednesday, the Institute for Clinical and Economic Review said most prices of PARP inhibitors are too high to align with estimated benefit in designated populations, and found insufficient evidence to compare PARP inhibitors across key ovarian cancer indications.

read article

PharmaMar Will Present New Clinical Data on PM1183 During ESMO 2017

(4 Traders) Aug 31, 2017 - Within the framework of this Congress, favorable data on the efficacy of PM1183 as a single agent and in combination in patients with small cell lung cancer will be presented; with respect to Yondelis®, PharmaMar will present, an indirect, adjusted comparison of trabectedin and pazopanib for the treatment of advanced metastatic leiomyosarcomas.

read article

AstraZeneca Highlights Latest Advances In Lung Cancer At The ESMO 2017 Congress

(AstraZeneca) Aug 31, 2017 - More than 40 presentations, including data from two pivotal trials selected as late-breaking abstracts for oral presentation in the ESMO Presidential Symposia; phase III PACIFIC data reinforce potential of Imfinzi following US FDA breakthrough therapy designation in locally-advanced (Stage III) unresectable NSCLC; phase III FLAURA results highlight superiority of Tagrisso over standard of care in previously-untreated patients with advanced EGFRm NSCLC.

read corporate press release

Clovis Oncology To Present Comprehensive Dataset From Successful ARIEL3 Clinical Trial Program At 2017 ESMO Congress

(Clovis) Aug 30, 2017 - Comprehensive results from Phase 3 ARIEL3 maintenance treatment trial of rucaparib in advanced ovarian cancer patients accepted as late-breaker presentation, will be highlighted in ESMO press program; posters outlining the designs of the ARIEL4 and TRITON clinical trial programs will also be presented.

read corporate press release

Does Baby Powder Cause Cancer? A Jury Says Yes. Scientists Aren't So Sure

(NPR/Shots) Aug 22, 2017 - If you're a woman, there's a good chance you've used Johnson's Baby Powder at some point. It smells good, and it can keep you dry.

read article

Celsion Announces Presentation of OVATION Study Findings at the Upcoming AACR Special Conference

(Yahoo! News) Aug 24, 2017 - Celsion Corporation (CLSN), an oncology drug development company, today provided an update on its OVATION Study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced (stage III/IV) ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery.

read article

Cancer Research UK Launches Trial To Test New Drug In Patients With Advanced Cancer

(Cancer Research UK) Aug 23, 2017 - A clinical trial to test a new cancer drug in patients with advanced solid tumours, launches in four centres* across the UK, through Cancer Research UK’s Centre for Drug Development.

read press release

L.A. Jury Hits Johnson & Johnson With $417-Million Verdict Over Cancer Link To Its Talc

(Los Angeles Times/L.A. Now) Aug 21, 2017 – A Los Angeles jury issued a $417-million verdict Monday against Johnson & Johnson, finding the company liable for failing to warn a 63-year-old woman diagnosed with terminal ovarian cancer about the risks of using its talcum products.

read article (free registration required)

Johnson and Johnson Ordered To Pay $417M In Case Linking Talcum Powder, Ovarian Cancer

(KHN Morning Briefing) Aug 22, 2017 - Eva Echeverria, 63, of East Los Angeles, is one of thousands of women who sued the consumer products giant, claiming Johnson's baby powder caused their disease.

read article
Next Page